Clinical Trial Update: A Study to Assess Anktiva in Patients With Long Covid-19. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Anktiva (N-803) for long COVID and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Anktiva (N-803)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Long COVID | Phase 2 | Status: RECRUITING